Fluralaner (INN) is a systemic insecticide and acaricide Fluralaner through potent blockage of GABA and L-glutamate gated chloride channels.
Fluralaner potently inhibits flea reproduction capacity in vitro. Oviposition ceases completely at concentrations as low as 25.0 ng/mL. While no ovicidal effect is observed, fluralaner exerts a larvicidal effect at exceptionally low concentrations (6.25 ng/mL)[1].
In the simulated flea-infested home environment, flea-control efficacy on fluralaner-treated dogs is >99% at every time point measured for 12 weeks. No adverse events are observed in fluralaner-treated dogs. Fluralaner completely controls egg laying, larval development and flea reproduction even at sub-insecticidal concentrations. Oral treatment of dogs with fluralaner is highly effective for eliminating fleas in a simulated flea-infested home environment[1]. After single oral administration of Bravecto chewable tablets, mite numbers in skin scrapings are reduced by 99.8% on Day 28 and by 100% on Days 56 and 84. A marked decrease is observed in the occurrence of erythematous patches, crusts, casts and scales in the dogs treated with Bravectco[2].
References:
[1]. Williams H, et al. Fluralaner, a novel isoxazoline, prevents flea (Ctenocephalides felis) reproduction in vitro and in asimulated home environment. Parasit Vectors. 2014 Jun 19;7:275.
[2]. Walther FM, et al. Safety of fluralaner, a novel systemic antiparasitic drug, in MDR1(-/-) Collies after oral administration. Parasit Vectors. 2014 Mar 6;7:86.